Rxsight, Inc. (RXST) — SEC Filings
Rxsight, Inc. (RXST) — 33 SEC filings. Latest: 8-K (Dec 23, 2025). Includes 12 8-K, 7 SC 13G/A, 6 10-Q.
View Rxsight, Inc. on SEC EDGAR
Overview
Rxsight, Inc. (RXST) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: On December 23, 2025, RxSight, Inc. filed an 8-K report detailing changes in its executive officers and board of directors. The filing also includes information regarding compensatory arrangements for certain officers and a Regulation FD disclosure. The company, formerly known as Calhoun Vision Inc.
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 29 neutral, 1 mixed. The dominant filing sentiment for Rxsight, Inc. is neutral.
Filing Type Overview
Rxsight, Inc. (RXST) has filed 12 8-K, 6 10-Q, 1 8-K/A, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of RXST's 17 recent filings, 1 were flagged as high-risk, 9 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $101.871M |
| Net Income | -$29.792M |
| EPS | -$0.73 |
| Debt-to-Equity | 0.12 |
| Cash Position | $29.633M |
| Operating Margin | -36.19% |
| Total Assets | $308.533M |
| Total Debt | $32.563M |
Key Executives
- David E. Johnson
- Dr. Arshad Khan
- Mr. David R. Johnson
- December 31, 2023
Industry Context
RxSight operates in the ophthalmic medical device industry, a sector characterized by significant R&D investment and stringent regulatory hurdles. The market is driven by technological innovation aimed at improving vision correction and treating eye diseases. Competition comes from established players and emerging companies offering a range of surgical and non-surgical solutions.
Top Tags
financial-condition (4) · 10-Q (4) · 8-K (3) · board-changes (2) · Medical Devices (2) · Cataract Surgery (2) · amendment (2) · Ophthalmic Goods (2) · SEC Filing (2) · corporate-governance (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Commission File Number | 001-40690 | Identifies the company's filing with the SEC |
| IRS Employer Identification No. | 94-3268801 | Company's tax identification number |
| Sales | $101.871M | Increased 2.16% for the nine months ended September 30, 2025, compared to $99.713 million in 2024. |
| Net Loss | $29.792M | Increased 38.46% for the nine months ended September 30, 2025, from $21.517 million in 2024. |
| Total Operating Expenses | $114.600M | Increased 16.49% for the nine months ended September 30, 2025, from $98.385 million in 2024. |
| Selling, General and Administrative Expenses | $84.956M | Increased from $73.225 million in 2024 to $84.956 million in 2025. |
| Research and Development Expenses | $29.644M | Increased from $25.160 million in 2024 to $29.644 million in 2025. |
| Cash and Cash Equivalents | $29.633M | Increased from $16.706 million at December 31, 2024, to $29.633 million at September 30, 2025. |
| Basic & Diluted Net Loss Per Share | $0.73 | Increased from $0.56 in 2024 to $0.73 in 2025 for the nine months ended September 30. |
| Common Stock Shares Outstanding | 41,116,640 | As of October 30, 2025, indicating potential dilution from prior periods. |
| Q2 2025 Revenue | $28.5M | Increased 41.8% from $20.1M in Q2 2024, showing strong product adoption. |
| Six-Month 2025 Revenue | $54.2M | Up 40.4% from $38.6M in the prior year, indicating sustained growth. |
| Q2 2025 Net Loss | -$15.3M | Improved from -$17.8M in Q2 2024, but still represents unprofitability. |
| Q2 2025 R&D Expense | $10.2M | Increased from $9.1M in Q2 2024, reflecting continued investment in innovation. |
| SEC File Number | 001-40690 | Identifies the company's filing with the SEC. |
Forward-Looking Statements
- {"claim":"RxSight's stock price may see a short-term positive reaction due to increased institutional interest.","entity":"RxSight, Inc.","targetDate":"2024-03-12","confidence":"medium"}
- {"claim":"Other institutional investors might initiate or increase their positions in RxSight, following Artisan Partners' lead.","entity":"RxSight, Inc.","targetDate":"2024-06-30","confidence":"low"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Rxsight, Inc. (RXST)?
Rxsight, Inc. has 33 recent SEC filings from Jan 2024 to Dec 2025, including 12 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RXST filings?
Across 33 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 29 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Rxsight, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Rxsight, Inc. (RXST) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Rxsight, Inc.?
Key financial highlights from Rxsight, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RXST?
The investment thesis for RXST includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Rxsight, Inc.?
Key executives identified across Rxsight, Inc.'s filings include David E. Johnson, Dr. Arshad Khan, Mr. David R. Johnson, December 31, 2023.
What are the main risk factors for Rxsight, Inc. stock?
Of RXST's 17 assessed filings, 1 were flagged high-risk, 9 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Rxsight, Inc.?
Recent forward-looking statements from Rxsight, Inc. include guidance on {"claim":"RxSight's stock price may see a short-term positive reaction due to increased institutional interest.","entity and 1 other predictions.